Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Ebastine Stories

2012-11-06 12:27:00

LEIDEN, Netherlands, November 6, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC(R) FIX Birch. This combined dose tolerability and dose range finding study will characterize the dose-response relationship of SUBLIVAC(R) FIX Birch in order to support the optimal dose in terms of clinical efficacy and safety. The multi-centre, randomized, double-blind, placebo-controlled study in...